Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Net Margin: 2013-2025

Historic Net Margin for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to 9.04%.

  • Amphastar Pharmaceuticals' Net Margin fell 1210.00% to 9.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.81%, marking a year-over-year decrease of 768.00%. This contributed to the annual value of 20.27% for FY2024, which is 87.00% down from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Net Margin is 9.04%, which was down 49.17% from 17.79% recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Net Margin registered a high of 27.59% during Q3 2021, and its lowest value of 3.84% during Q1 2021.
  • In the last 3 years, Amphastar Pharmaceuticals' Net Margin had a median value of 18.74% in 2023 and averaged 18.79%.
  • In the last 5 years, Amphastar Pharmaceuticals' Net Margin skyrocketed by 2,256bps in 2021 and then slumped by 1,424bps in 2022.
  • Over the past 5 years, Amphastar Pharmaceuticals' Net Margin (Quarterly) stood at 16.52% in 2021, then soared by 515bps to 21.67% in 2022, then plummeted by 293bps to 18.74% in 2023, then plummeted by 467bps to 14.07% in 2024, then crashed by 1,210bps to 9.04% in 2025.
  • Its Net Margin was 9.04% in Q3 2025, compared to 17.79% in Q2 2025 and 14.83% in Q1 2025.